You are here

Samsung Bioepis seeks Europe's nod for its Humira drug copy

Wednesday, July 20, 2016 - 05:50
BT_20160720_BIOEPIS_2394385.jpg
Samsung hopes its biosimilar company can emerge as a new growth driver.

Seoul

BIOSIMILARS maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group, said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

Samsung Bioepis said that the European Medicines